Investors take note of Opthea’s potential

Australian biotech company Opthea has reported a solid cash position to further advance clinical trials of its lead drug candidate OPT-302 in FY20, as it moves closer to imposing itself on the macular disease market. Read more

Menicon launches new daily disposable CL

O=MEGA PREVIEW: Menicon Australia will be introducing the newest addition to the Miru family of contact lenses.The company will launch Miru 1day UpSide, the first and only silicone hydrogel daily disposable contact lens incorporated with the manufacturer’s Smart Touch technology. Read more